Clinical Trial Update: HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1) [Phase 1]

View source ↗

Summary

This document summarizes a Phase 1 clinical trial evaluating an HLA-A*0201 restricted peptide vaccine in combination with gemcitabine for pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• HLA-A*0201 restricted peptide vaccine

Snippet

Sponsor: Fukushima Medical University | Conditions: Pancreatic Cancer | Phase 1 | Status: UNKNOWN